Insights

Clinical momentum Climb Bio is actively advancing immune-mediated disease programs with visible activity at major nephrology conferences, signaling ongoing clinical data generation and potential partner interest. This creates opportunities to engage investigators, payers, and CROs involved in ASN Kidney Week and related events.

Strategic partnerships Recent financing moves include a substantial private placement and a new Jefferies program after ending the prior agreement, indicating readiness to scale trials and pursue collaborations, licensing, or co-development deals with larger biotech or pharmaceutical companies.

Financing runway With a total funding pool of over half a billion dollars and a multi-phase clinical agenda, Climb Bio is positioned to seek partnerships for milestone-driven deals, exploratory studies, or service agreements to extend trial capabilities and accelerate reach into kidney disease indications.

Commercial readiness Investments in regulatory and commercial preparation appear ongoing, as evidenced by investor communications and executive leadership appointment, suggesting interest in building market access, medical affairs, and health economics capabilities to support future product launches.

Technology & data A focus on novel antibody programs such as CLYM116 targeting APRIL for IgA nephropathy, along with Phase II China studies, points to collaborations around translational science, biomarker development, and data-driven trial design with CROs and biopharma tech partners.

Similar companies to Climb Bio

Climb Bio Tech Stack

Climb Bio uses 8 technology products and services including iCIMS, Canva, WordPress, and more. Explore Climb Bio's tech stack below.

Media & News

Climb Bio's Email Address Formats

Climb Bio uses at least 3 email formats:
Climb Bio Email FormatsExamplePercentage
First.Last@climbbio.comJohn.Doe@climbbio.com
94%
First.Middle@climbbio.comJohn.Michael@climbbio.com
6%
First.Last@eliemtx.comJohn.Doe@eliemtx.com
100%

Frequently Asked Questions

What is Climb Bio's stock symbol?

Minus sign iconPlus sign icon
Climb Bio is a publicly traded company; the company's stock symbol is CLYM.

What is Climb Bio's official website and social media links?

Minus sign iconPlus sign icon
Climb Bio's official website is climbbio.com and has social profiles on LinkedIn.

How much revenue does Climb Bio generate?

Minus sign iconPlus sign icon
As of October 2026, Climb Bio's annual revenue is estimated to be $10M - $25M.

What is Climb Bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
Climb Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Climb Bio have currently?

Minus sign iconPlus sign icon
As of October 2026, Climb Bio has approximately 47 employees across 3 continents, including North America, Europe and Oceania. Key team members include Chief Medical Officer: E. D. C., Chief Operating Officer And Chief Financial Officer: E. L. and Clinical Trial Manager: M. B. Explore Climb Bio's employee directory with LeadIQ.

What industry does Climb Bio belong to?

Minus sign iconPlus sign icon
Climb Bio operates in the Biotechnology Research industry.

What technology does Climb Bio use?

Minus sign iconPlus sign icon
Climb Bio's tech stack includes iCIMS, Canva, WordPress, NetSuite, Mimecast, Veeva Systems, WP Engine and Smartsheet.

What is Climb Bio's email format?

Minus sign iconPlus sign icon
Climb Bio's email format typically follows the pattern of First.Last@climbbio.com. Find more Climb Bio email formats with LeadIQ.

How much funding has Climb Bio raised to date?

Minus sign iconPlus sign icon
As of October 2026, Climb Bio has raised $521M in funding. The last funding round occurred on Apr 28, 2026.

When was Climb Bio founded?

Minus sign iconPlus sign icon
Climb Bio was founded in 2018.
Climb Bio logo

Climb Bio

Biotechnology ResearchMassachusetts, United States11-50 Employees

Climb Bio is a biotechnology research company focused on immune-mediated diseases, where the immune system targets the body's tissues and can cause organ damage or death. The company aims to modulate the pathways that drive these diseases to extend the period patients live without active disease when current therapies fall short. Its work addresses conditions affecting a substantial share of the population, highlighting an unmet medical need in immune-related disorders.

Based in Wellesley, Massachusetts, the organization functions as a small to mid-sized enterprise within the biotech sector. In 2025 it entered into an exclusive license for MIL116 (now CLYM116) for development outside Greater China, and the company has engaged with the scientific community at industry events such as Kidney Week 2025.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
CLYM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $521M

    Climb Bio has raised a total of $521M of funding over 8 rounds. Their latest funding round was raised on Apr 28, 2026 as a Post IPO Equity.

  • $10M - $25M

    Climb Bio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.